554 related articles for article (PubMed ID: 27310712)
21. Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States.
Hunt B; McConnachie CC; Gamble C; Dang-Tan T
J Med Econ; 2017 Nov; 20(11):1117-1120. PubMed ID: 28651479
[TBL] [Abstract][Full Text] [Related]
22. Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus.
Capel M; Ciudin A; Mareque M; Rodríguez-Rincón RM; Simón S; Oyagüez I
Pharmacoecon Open; 2020 Jun; 4(2):277-286. PubMed ID: 31338828
[TBL] [Abstract][Full Text] [Related]
23. Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US.
Samyshkin Y; Guillermin AL; Best JH; Brunell SC; Lloyd A
J Med Econ; 2012; 15 Suppl 2():6-13. PubMed ID: 22793669
[TBL] [Abstract][Full Text] [Related]
24. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M
Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244
[TBL] [Abstract][Full Text] [Related]
25. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
Valentine WJ; Palmer AJ; Lammert M; Langer J; Brändle M
Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies.
Suzuki S; Oura T; Takeuchi M; Boye KS
Health Qual Life Outcomes; 2017 Jun; 15(1):123. PubMed ID: 28606095
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.
Jendle J; Grunberger G; Blevins T; Giorgino F; Hietpas RT; Botros FT
Diabetes Metab Res Rev; 2016 Nov; 32(8):776-790. PubMed ID: 27102969
[TBL] [Abstract][Full Text] [Related]
28. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
Johnston SS; Nguyen H; Cappell K; Nelson JK; Chu BC; Kalsekar I
J Med Econ; 2015; 18(9):666-77. PubMed ID: 25867133
[TBL] [Abstract][Full Text] [Related]
29. [Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes].
Scheen AJ
Rev Med Liege; 2016 Mar; 71(3):154-60. PubMed ID: 27311248
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
Gu S; Wang X; Qiao Q; Gao W; Wang J; Dong H
Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
[TBL] [Abstract][Full Text] [Related]
31. Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics.
Risebrough NA; Baker TM; Zhang L; Ali SN; Radin M; Dang-Tan T
Clin Ther; 2021 Nov; 43(11):1812-1826.e7. PubMed ID: 34728099
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapies.
Deng J; Gu S; Shao H; Dong H; Zou D; Shi L
J Med Econ; 2015; 18(11):974-89. PubMed ID: 26134916
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece.
Tzanetakos C; Melidonis A; Verras C; Kourlaba G; Maniadakis N
BMC Health Serv Res; 2014 Sep; 14():419. PubMed ID: 25245666
[TBL] [Abstract][Full Text] [Related]
34. Network meta-analysis accurately predicted the outcome of a subsequent randomised trial comparing once weekly dulaglutide 1.5 mg and once daily liraglutide 1.8 mg.
Fahrbach JL; Fu H; Shurzinske L; Skrivanek Z; Martin S
Int J Clin Pract; 2016 Mar; 70(3):218-21. PubMed ID: 26916354
[TBL] [Abstract][Full Text] [Related]
35. Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan.
Onishi Y; Oura T; Matsui A; Matsuura J; Iwamoto N
Endocr J; 2017 May; 64(5):553-560. PubMed ID: 28367916
[TBL] [Abstract][Full Text] [Related]
36. Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
Nauck MA; Frossard JL; Barkin JS; Anglin G; Hensley IE; Harper KD; Milicevic Z
Diabetes Care; 2017 May; 40(5):647-654. PubMed ID: 28283565
[TBL] [Abstract][Full Text] [Related]
37. Cost Effectiveness of Dulaglutide Compared with Liraglutide and Glargine in Type 2 Diabetes Mellitus Patients in Colombia.
Lasalvia P; Baquero L; Otálora-Esteban M; Castañeda-Cardona C; Rosselli D
Value Health Reg Issues; 2017 Dec; 14():35-40. PubMed ID: 29254540
[TBL] [Abstract][Full Text] [Related]
38. Long-Term Effectiveness and Cost-Effectiveness of Metformin Combined with Liraglutide or Exenatide for Type 2 Diabetes Mellitus Based on the CORE Diabetes Model Study.
Zhang X; Liu S; Li Y; Wang Y; Tian M; Liu G
PLoS One; 2016; 11(6):e0156393. PubMed ID: 27304904
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting.
Hunt B; Vega-Hernandez G; Valentine WJ; Kragh N
Diabetes Obes Metab; 2017 Jun; 19(6):842-849. PubMed ID: 28124820
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.
Yuan S; Wu Y
Front Public Health; 2023; 11():1201818. PubMed ID: 37744474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
